Prospective evaluation of growth, nutritional status, and body composition in children with cystic fibrosis

American Journal of Clinical Nutrition

Volumn 72, Issue 2, 2000, Pages 407-413

  Stettler, N ^a   Kawchak, D A ^a   Boyle, L L ^a   Propert, K J ^a   Scanlin, T F ^a   Stallings, V A ^a   Zemel, B S ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Body composition; Children; Cystic fibrosis; Deuterium oxide; Genotype; Growth; Longitudinal studies; Mixed effects model; Nutritional status; Respiratory function tests; Total body water; Total body electrical conductivity

Indexed keywords

ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WATER; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CYSTIC FIBROSIS; ELECTRIC CONDUCTIVITY; FEMALE; GENOTYPE; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION; MALE; NUTRITIONAL STATUS; PROSPECTIVE STUDY;

EID: 0033858924     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/72.2.407     Document Type: Article

References (36)

1. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto
2. Prediction of mortality in patients with cystic fibrosis
3. Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish center
4. Gender gap in cystic fibrosis mortality
5. Inspiratory muscle function and body composition in cystic fibrosis
6. Comparison of growth status of patient with cystic fibrosis between the United States and Canada
7. Body composition of adult cystic fibrosis patients and control subjects as determined by densitometry, bioelectrical impedance, total-body electrical conductivity, skinfold measurements, and deuterium oxide dilution
8. Comparison of three techniques for body composition analysis in cystic fibrosis
9. Body composition of children with cystic fibrosis with mild clinical manifestations compared with normal children
10. Identification of the cystic fibrosis gene: Genetic analysis
11. The methods of auxologic anthropometry
12. Growth in adolescence
13. New norms of upper limb fat and muscle areas for assessment of nutritional status
14. The assessment of the amount of fat in the human body from measurements of skinfold thickness
15. Determination of body composition of children from skinfold measurements
16. 2H labeled water
17. Energy expenditure and genotype of children with cystic fibrosis
18. Hydration of the fat-free body in children during maturation
19. Methods for assessment of human body composition: Traditional and new
20. Assessment of fat-free mass in teen-agers: Use of TOBEC methodology
21. Physical growth: National Center for Health Statistics percentiles
22. Random-effects models for longitudinal data
23. Changes in body composition and muscle protein degradation during nutritional supplementation in nutritionally growth-retarded children with cystic fibrosis
24. Evaluation of growth and changes in body composition following neonatal diagnosis of cystic fibrosis
25. Bio-electrical impedance analysis for estimation of fat-free mass and muscle mass in cystic fibrosis patients
26. Body composition analysis by dual-energy x-ray absorptiometry in adults with cystic fibrosis
27. Assessment of body composition of children with cystic fibrosis (CF)
28. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group
29. Linear growth in children with cystic fibrosis I. Birth to 8 years of age
30. Bone density in children and adolescents with cystic fibrosis
31. Bone acquisition and loss in children and adults with cystic fibrosis: A longitudinal study
32. Body fat assessed from body density and estimated from skinfold thickness in normal children and children with cystic fibrosis
33. Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function, and genotype in children with cystic fibrosis
34. Longitudinal, prospective analysis of dietary intake in children with cystic fibrosis
35. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis